期刊简介
本杂志由中华人民共和国卫生部主管，复旦大学医学院（原上海医科大学）主办，国内外公开发行的国家级医学学术期刊，双月刊，逢双月出版，主要刊载感染性疾病与抗感染化疗领域的最新科研成果、新技术、新方法及最新临床经验，主要读者对象为临床各科医师、医院药剂科工作人员、临床微生物检验人员及从事抗感染化疗的药理学、临床药理学、临床微生物学和临床药学研究的各级人员。
往期目录
-
2001
-
2002
-
2003
-
2004
-
2005
-
2006
-
2007
-
2008
-
2009
-
2010
-
2011
-
2012
-
2013
-
2014
-
2015
-
2016
-
2017
-
2018
首页>中国感染与化疗杂志
- 杂志名称：中国感染与化疗杂志
- 主管单位：中华人民共和国教育部
- 主办单位：复旦大学附属华山医院
- 国际刊号：1009-7708
- 国内刊号：31-1965/R
- 出版周期：双月刊
期刊荣誉：中国期刊全文数据库(CJFD)期刊收录：知网收录(中), 统计源核心期刊(中国科技论文核心期刊), 国家图书馆馆藏, 医学文摘, 文摘与引文数据库, CA 化学文摘(美), 上海图书馆馆藏, 北大核心期刊(中国人文社会科学核心期刊), CSCD 中国科学引文数据库来源期刊(含扩展版), 维普收录(中), 万方收录(中)
Extended-spectrum β-lactamase controversies
关键词：amino acid, active site
摘要：What is an ESBL?What seemed like a simple concept when the name ESBL was introduced has become more complicated as more enzymes with related properties have been recognized. The first enzymes to be termed extended-spectrum β-lactamases (ESBLs) were found to differ from the common, plasmid-mediated, broadspectrum SHV-1, TEM-1, or TEM-2 β-lactamases by a small number of amino acid substitutions located near the active site that modified its structure so as to extend the spectrum of the parental enzyme[1-3]. Later ESBLs related to OXA-2 or OXA-10 were discovered that also differed from their progenitors by a limited number of amino acid substitutions[4-5]. These enzymes conferred resistance to oxyirnino-β-lactams such as cefotaxime, ceftazidime, ceftriaxone, and aztreonam and were at least as susceptible to β-lactamase inhibitors (clavulanic acid or sulbactam) as the parental types (with the OXA enzymes notably less susceptible than those in the TEM or SHV families)[6].
友情链接